Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      Korean Society of Hematology Acute myeloid Leukemia/Myelodysplastic Syndrome Working Party
    • Source:
      Publisher: Springer Japan Country of Publication: Japan NLM ID: 9111627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-3774 (Electronic) Linking ISSN: 09255710 NLM ISO Abbreviation: Int J Hematol Subsets: MEDLINE
    • Publication Information:
      Publication: 2008- : Tokyo : Springer Japan
      Original Publication: Amsterdam : Elsevier Science Publishers, c1991-
    • Subject Terms:
      Antimetabolites, Antineoplastic/*therapeutic use ; Azacitidine/*therapeutic use ; DNA (Cytosine-5-)-Methyltransferases/*antagonists & inhibitors ; Myelodysplastic Syndromes/*drug therapy; Adolescent ; Adult ; Aged ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Male ; Middle Aged ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/mortality ; Myelodysplastic Syndromes/therapy ; Preoperative Care ; Retrospective Studies ; Transplantation, Homologous ; Treatment Outcome ; Young Adult
    • Abstract:
      Allogeneic hematopoietic stem cell transplantation (alloSCT) is currently the only curative treatment modality for myelodysplastic syndromes (MDS). The treatment paradigm for MDS has changed in recent years with the introduction of hypomethylating agents (HMAs). The present retrospective multicenter study was designed to assess the effects of pre-transplant HMA on transplant outcome and determine which patients would benefit most from this therapy. A total of 109 patients who received alloSCT at one of five institutions between 2007 and 2010 were enrolled in this study regardless of pre-transplant HMA therapy. 81 of the 109 patients enrolled were treated with HMA prior to alloSCT. 28 patients received alloSCT without HMA bridging. The distributions of WHO classification groups and IPSS scores were similar between the two groups (P = 0.752 and P = 0.265, respectively). Pre-transplant HMA did not affect OS (P = 0.244), and there were no differences in response to HMA therapy within the HMA-treated group. The cumulative incidence of NRM was not significantly different between the two groups (P = 0.500). However, for patients with a high blast count (>5 % of bone marrow at the time of diagnosis), pre-transplant HMA therapy had a NRM benefit (83.3 vs. 48.6 %, P = 0.014).
    • References:
      Hematology Am Soc Hematol Educ Program. 2010;2010:325-9. (PMID: 21239814)
      Haematologica. 2002 Dec;87(12):1324-41. (PMID: 12495905)
      Blood. 2002 Aug 15;100(4):1201-7. (PMID: 12149198)
      Hematology Am Soc Hematol Educ Program. 2006;:205-10. (PMID: 17124062)
      Cancer. 2007 Mar 15;109(6):1133-7. (PMID: 17315156)
      Biol Blood Marrow Transplant. 2007 Apr;13(4):454-62. (PMID: 17382251)
      Prog Clin Biol Res. 1983;134:457-74. (PMID: 6198660)
      Blood. 2002 Mar 15;99(6):1943-51. (PMID: 11877264)
      Bone Marrow Transplant. 2010 Feb;45(2):255-60. (PMID: 19543327)
      Semin Cancer Biol. 1999 Oct;9(5):359-67. (PMID: 10547344)
      Bone Marrow Transplant. 1998 Feb;21(3):255-61. (PMID: 9489648)
      Crit Rev Oncol Hematol. 2010 Dec;76(3):218-27. (PMID: 20451404)
      J Clin Oncol. 2002 May 15;20(10):2429-40. (PMID: 12011120)
      Leukemia. 1993 May;7 Suppl 1:42-8. (PMID: 7683356)
      Blood. 1996 Jul 1;88(1):358-65. (PMID: 8704196)
      Blood. 2002 Sep 15;100(6):1997-2004. (PMID: 12200358)
      Am J Med. 1980 Aug;69(2):204-17. (PMID: 6996481)
      Cancer. 2006 Apr 15;106(8):1794-803. (PMID: 16532500)
      Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S37-44. (PMID: 19857589)
      Eur J Haematol. 2013 Feb;90(2):111-20. (PMID: 23113470)
      J Clin Oncol. 2000 Mar;18(5):963-71. (PMID: 10694545)
      Hum Genet. 1983;64(4):315-33. (PMID: 6194100)
      Blood. 2006 Jul 15;108(2):419-25. (PMID: 16609072)
      Adv Cancer Res. 1998;72:141-96. (PMID: 9338076)
      Cell. 1980 May;20(1):85-93. (PMID: 6156004)
      Bone Marrow Transplant. 2009 Jun;43(11):839-43. (PMID: 19151791)
      Blood. 1993 Jul 15;82(2):677-81. (PMID: 8329721)
      Leukemia. 2000 Nov;14(11):1915-20. (PMID: 11069027)
      Blood. 2007 Feb 15;109(4):1395-400. (PMID: 17038533)
      N Engl J Med. 2005 Feb 10;352(6):536-8. (PMID: 15703418)
    • Accession Number:
      0 (Antimetabolites, Antineoplastic)
      EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases)
      M801H13NRU (Azacitidine)
    • Publication Date:
      Date Created: 20140321 Date Completed: 20150413 Latest Revision: 20211021
    • Publication Date:
      20231215
    • Accession Number:
      10.1007/s12185-014-1549-3
    • Accession Number:
      24648120